Cerrissa Hugie, APRN
Psychiatric/Mental Health · Charleston, SCNPI 1538695846
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,175 of the $53,802 with a category attached, or 80.2%. AbbVie accounts for 85.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $25,837 and has fallen 89.9% since, to $2,616 in 2025. Among psychiatric/mental health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 524 payments — averaging $102.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Biogen$2K
- Vanda Pharmaceuticals Inc.$694
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$686
- Lundbeck LLC$592
- Takeda Pharmaceuticals U.S.A., Inc.$536
- plus $4K from 20 others
What the payments were for
- Consulting fees$1,6173%
- Speaking & faculty fees$43,17580%
- Travel & lodging$1,1752%
- Food & beverage$7,66314%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 207 | $45,768 |
| Biogen | 1 | $1,617 |
| Vanda Pharmaceuticals Inc. | 34 | $694 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $686 |
| Lundbeck LLC | 28 | $592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $536 |
| Otsuka America Pharmaceutical, Inc. | 30 | $489 |
| Alkermes, Inc. | 26 | $461 |
| Axsome Therapeutics, Inc. | 19 | $431 |
| Johnson & Johnson | 22 | $399 |
| Teva Pharmaceuticals USA, Inc. | 18 | $397 |
| Supernus Pharmaceuticals, Inc. | 14 | $287 |
| Corium, LLC | 17 | $261 |
| Harmony Biosciences LLC | 9 | $223 |
| Neurocrine Biosciences, Inc. | 7 | $190 |
| Sunovion Pharmaceuticals Inc. | 8 | $165 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $126 |
| Neos Therapeutics, LP | 6 | $103 |
| Sage Therapeutics, LLC | 3 | $102 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Tris Pharma Inc | 4 | $74 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Almatica Pharma LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Tempus AI, Inc | 1 | $20 |
| Indivior Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,802 in reported general payments places this provider in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $43,461 |
| SpravatoEsketamine Hcl | 11 | $33,098 |
| VivitrolNaltrexone Microspheres | 13 | $20,833 |
| TrintellixVortioxetine Hydrobromide | 13 | $7,478 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $1,422 |
| Quetiapine Fumarate | 90 | $1,297 |
| Naltrexone Hcl | 15 | $1,095 |
| Trazodone Hcl | 65 | $876 |
| Aripiprazole | 40 | $828 |
| Clonazepam | 87 | $722 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $664 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $544 |
| Hydroxyzine Hcl | 25 | $439 |
| Escitalopram Oxalate | 23 | $400 |
| Bupropion XlBupropion Hcl | 37 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $45,768 | $43,46128 claims |
| Johnson & JohnsonSpravato | $399 | $33,09811 claims |
| Alkermes, Inc.Vivitrol | $461 | $20,83313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $536 | $7,47813 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $24436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Charleston
- Lauren StephanCharleston$8K
- Samantha WadfordCharleston$4K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
- Kelsie FowlerAnderson$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.